Durrani K - Search Results

1

Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid.

Kim IK, Husain D, Michaud N, Connolly E, Lane AM, Durrani K, Hafezi-Moghadam A, Gragoudas ES, O'Neill CA, Beyer JC, Miller JW. Kim IK, et al. Among authors: durrani k. Invest Ophthalmol Vis Sci. 2006 Jan;47(1):357-63. doi: 10.1167/iovs.04-0087. Invest Ophthalmol Vis Sci. 2006. PMID: 16384985

2

Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety.

Durrani K, Papaliodis GN, Foster CS. Durrani K, et al. Ophthalmology. 2004 May;111(5):960-5. doi: 10.1016/j.ophtha.2003.08.034. Ophthalmology. 2004. PMID: 15121375 Clinical Trial.

3

Psoriatic uveitis: a distinct clinical entity?

Durrani K, Foster CS. Durrani K, et al. Am J Ophthalmol. 2005 Jan;139(1):106-11. doi: 10.1016/j.ajo.2004.08.053. Am J Ophthalmol. 2005. PMID: 15652834

4

Fundus autofluorescence imaging in posterior uveitis.

Durrani K, Foster CS. Durrani K, et al. Semin Ophthalmol. 2012 Sep-Nov;27(5-6):228-35. doi: 10.3109/08820538.2012.711414. Semin Ophthalmol. 2012. PMID: 23163281 Review.

5

Adamantiades-Behcet disease: diagnosis and current concepts in management of ocular manifestations.

Durrani K, Ahmed M, Foster CS. Durrani K, et al. Compr Ophthalmol Update. 2007 Jul-Aug;8(4):225-33. Compr Ophthalmol Update. 2007. PMID: 17999836 Review.

6

The genetics of Adamantiades-Behcet's disease.

Durrani K, Papaliodis GN. Durrani K, et al. Semin Ophthalmol. 2008 Jan-Feb;23(1):73-9. doi: 10.1080/08820530701745264. Semin Ophthalmol. 2008. PMID: 18214795 Review.

7

Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease.

Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS, Foster CS. Durrani K, et al. Surv Ophthalmol. 2011 Nov-Dec;56(6):474-510. doi: 10.1016/j.survophthal.2011.05.003. Surv Ophthalmol. 2011. PMID: 22117884 Review.

8

Adalimumab for Ocular Inflammation.

Durrani K, Kempen JH, Ying GS, Kacmaz RO, Artornsombudh P, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Foster CS Md Facs, Systemic Immunosuppressive Therapy For Eye Diseases Site Research Group. Durrani K, et al. Ocul Immunol Inflamm. 2017 Jun;25(3):405-412. doi: 10.3109/09273948.2015.1134581. Epub 2016 Mar 22. Ocul Immunol Inflamm. 2017. PMID: 27003323 Free PMC article.

9

Authors Reply to Letter to the Editor- In Response to: Comment on Durrani et al.'s "Adalimumab for Ocular Inflammation".

Durrani K, Kempen JH, Foster CS; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group. Durrani K, et al. Ocul Immunol Inflamm. 2019;27(1):71. doi: 10.1080/09273948.2017.1379545. Epub 2017 Oct 18. Ocul Immunol Inflamm. 2019. PMID: 29043914 No abstract available.

10

NONPARANEOPLASTIC AUTOIMMUNE RETINOPATHY VERSUS PERICENTRAL RETINAL DEGENERATION PHENOTYPE: WHICH CAME FIRST? A CASE REPORT.

Garcia CM, Maleki A, Look-Why S, Manhapra A, Durrani K, Foster CS. Garcia CM, et al. Among authors: durrani k. Retin Cases Brief Rep. 2023 Jul 1;17(4):384-388. doi: 10.1097/ICB.0000000000001199. Retin Cases Brief Rep. 2023. PMID: 34618714

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42 results

Search Page